Personalized Medicine- Genomic Test For Breast Cancer Recurrence Found To Be Cost-Effective

Published Jul 2, 2013
Toronto, ON, Canada – Personalized medicine offers the promise of more effective results through individualized therapy. By tailoring treatments to only those who may benefit, patient outcomes might be improved. However, personalized medicine tests are often expensive. Breast cancer is a complex disease that affects 1 in 9 Canadian women during their lifetime. Studies have shown that 1 in 29 women in Canada will die from it. For patients with early breast cancer, it is often difficult for doctors to decide whether to provide chemotherapy following surgery. This decision is based on clinical judgement, often supplemented by a free online decision aid. A new personalized genomic test allows for more individualized therapy by providing additional information regarding a patient’s risk of cancer recurrence, at a cost of approximately US $4,000 per patient. Researchers at the Toronto Health Economics and Technology Assessment (THETA) Collaborative at the University of Toronto evaluated the cost-effectiveness of using the genomic test, in conjunction with the online decision aid, for patients with early stage breast cancer that is hormone receptor-positive and HER2-negative. The results revealed that using the genomic test is cost-effective. This was the first study to also consider the cost-effectiveness of providing patients with chemotherapy, conditional upon their risk classification. Chemotherapy appears to be cost-effective for patients at intermediate or high risk using the genomic test, although this finding is uncertain for some patients at intermediate risk. Due to its high per-test cost, incorporating the genomic test into the health care system will not reduce costs overall. However, for many patients, the genomic test will show that chemotherapy is unnecessary, eliminating unwarranted treatment and its associated costs, and providing better health outcomes. In other patients, the genomic test will better identify the risk of cancer recurrence and ensure that patients receive the timely and effective treatment that best meets their needs. “Our findings will be of considerable interest to policy makers, health care providers, and clinicians faced with a climate of constrained resources and the difficult decision of whether to provide chemotherapy, particularly to intermediate risk patients,” said Mike Paulden, MSc, a health economist at the THETA Collaborative who led the research. “Despite the high cost of the test, this study suggests that this is a good use of health care dollars. We will continue to refine our analysis as more evidence becomes available on this and other genomic tests.” The full study, “Cost-Effectiveness of the 21-Gene Assay for Guiding Adjuvant Chemotherapy Decisions in Early Breast Cancer,” is published in Value in Health.

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information: www.ispor.org

Related Stories

Advancing the Economics of Mental Health: A Global Perspective

Mar 12, 2025

Value in Health, the official journal of ISPOR announced the publication of a special themed section of research papers exploring mental health economics, highlighting impacts on caregivers, productivity, and interventions’ cost-effectiveness.

Generative AI Set to Reshape Health Technology Assessment, ISPOR Report Finds

Feb 11, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of an ISPOR Working Group Report that provides an introduction to the uses of generative artificial intelligence (AI) in health technology assessment (HTA).

ISPOR Tackles Health Disparities with New Research Primer

Jan 22, 2025

ISPOR announced today the publication of a report from the ISPOR Health Equity Research Special Interest Group intended to establish key concepts for conducting health equity research that enables investigators to examine—and ultimately reduce—unfair social inequities in health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×